Dose-dense intensified sequential versus conventionally-dosed anthracycline and taxane-containing neoadjuvant therapy in patients with inflammatory breast cancer

Anticancer Research

Volumn 32, Issue 8, 2012, Pages 3539-3546

  Ditsch, Nina ^a   Vodermaier, A ^a,b   Hinke, A ^c   Burghardt, S ^d   Lenhard, M ^a   Lohrs B ^e   Toth, B ^f   Von Koch, F ^g   Kahlert, S ^a   Bauerfeind, I ^e   Konecny, G E ^h   Loibl, S ⁱ   Von Minckwitz, G ^i,j   Untch, M ^k  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c WiSP Wissenschaftlicher Service Pharma GmbH   (Germany)

^d Department of Obstetrics and Gynaecology   (Germany)

^e Klinikum Landshut   (Germany)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g Department of Obstetrics and Gynaecology   (Germany)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ GBG Forschungs GmbH   (Germany)

^j GOETHE UNIVERSITY   (Germany)

^k HELIOS Clinic   (Germany)

more..

Author keywords

Anthracyclines; Dose dense chemotherapy; Inflammatory breast cancer; Neoadjuvant chemotherapy; Taxanes

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADJUVANT CHEMOTHERAPY; ADULT; ALLERGY; ALOPECIA; ANEMIA; ARTICLE; BLEEDING; CANCER SURVIVAL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG RESPONSE; DYSPNEA; FEMALE; FEVER; HEART FAILURE; HEMATURIA; HUMAN; INFECTION; INFLAMMATORY BREAST CANCER; LEUKOPENIA; MAJOR CLINICAL STUDY; MASTECTOMY; MULTICENTER STUDY; NEUROPATHY; NEUTROPENIA; PAIN; PARTIAL MASTECTOMY; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIRUBICIN; FEMALE; HUMANS; INFLAMMATORY BREAST NEOPLASMS; MIDDLE AGED; PACLITAXEL; TREATMENT OUTCOME;

EID: 84865807326     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Low JA, Berman AW, Steinberg SM, Danforth DN, Lippmann ME and Swain SM: Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol 22(20): 4067-4074, 2004.
2. Gonzalez-Angulo AM, Sneige N, Buzdar AU, Valero V, Kau SW, Broglio K, Yamamura Y, Hortobagyi GN and Cristofanilli M: p53 expression as a prognostic marker in inflammatory breast cancer. Clin Cancer Res 10: 6215-6221, 2004.
3. Jaiyesimi IA, Buzdar AU and Hortobagyi G: Inflammatory breast cancer: A review. J Clin Oncol 10(6): 1014-1024, 1992.
4. Liauw SL, Benda RK, Morris CG and Mendenhall NP: Inflammatory breast carcinoma: Outcomes with trimodality therapy for nonmetastatic disease. Cancer 100(5): 920-928, 2004.
5. Panades M, Olivotto IA, Speers CH, CH, Shenkier T, Olivotto TA, Weir L, Allan SJ and Truong PT: Evolving treatment strategies for inflammatory breast cancer: A population-based survival analysis. J Clin Oncol 23(9): 1941-1950, 2005.
6. Shen J, Valero V, Buchholz TA, Singletary SE, Ames FC, Ross MI, Cristofanilli M, Babiera GV, Meric-Bernstam F, Feig B, Hunt KK and Kuerer HM: Effective local control and long-term survival in patients with T4 locally advanced breast cancer treated with breast conservation therapy. Ann Surg Oncol 11: 854-860, 2004.
7. Untch M, Konecny G, Ditsch N, Sorokina Y, Moebus V, Muck B, Kuhn W, Bastert G, Werner Ch, Thomssen Ch, Wallwiener D, Albert U, Bothmann G, Kreienberg R and Lück HJ: Dose-dense sequential epirubicin-paclitaxel as preoperative treatment of breast cancer. Results of a randomized AGO study. Proc Am Soc Clin Oncol 21(suppl; abstr 133): 34a, 2002.
8. Untch M, Möbus V, Kuhn W, Muck BR, Thomssen C, Bauerfeind I, Harbeck N, Lebeau A, Schneeweis A, Kahlert S, von Koch F, Petry KU, Wallwiener D, Kreinberg R, Albert US, Lück HJ, Hinke A, Jänicke F and Konecny GE: Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. J Clin Oncol 27(18): 2938-2945, 2009.
9. Costa SD, Loibl S, Kaufmann M, Zahm DM, Hilfrich J, Huober J, Eidtmann H, du Bois A, Blohmer JU, Ataseven B, Weiss E, Tesch H, Gerber B, Baumann KH, Thomssen C, Breitbach GP, Ibishi S, Jackisch C, Mehta K, von Minckwitz G: Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio Trial data. J Clin Oncol 28(1): 83-91, 2010.
10. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei E 3rd, Schilsky RL, Wood WC, Muss HB and Norton L: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21(6): 976-983, 2003.
11. Jakesz R, Gebhard B, Gnant M and Taucher S: Indications and contraindications for breast preservation in patients with breast cancer. Review Chirurg 70(4): 394-399, 1999.
12. Kell MR and Morrow M: Surgical aspects of inflammatory breast cancer. Breast Dis 22: 67-73, 2005.
13. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB and Norton L: Randomised trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21(8): 1431-1439, 2003; erratum in: J Clin Oncol 21(11): 2226, 2003.
14. Untch M, Fasching A, Konecny EG, Hasmüller S, Lebeau A, Kreinberg R, Camara O, Müller V, du Bois A, Kühn T, Stickeler E, Harbeck N, Höss C, Kahlert S, Beck T, Fett W, Mehta KM, von Minckwitz G and Loibl S: Patholgic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favourable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: Results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol 29(25): 3351-3357, 2011.
15. Gianni L, Eiermann W, Semiglazov V,Manikhas A, Lluch A, Tjulandin S, Zambetti M, Vazquez F, Byakhow M, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Baronio R, Feyereislova A, Barton C, Valagussa P and Baselga J: Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (NOAH trial): A randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375(9712): 377-384, 2010.
16. Untch M, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Hanusch C, Kühn T, du Bois A, Blohmer JU, Thomssen C, Da Costa S, Jackisch C, Kaufmann M, Mehta K and von Minckwitz G: Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol 28(12): 2024-2031, 2010.
17. Frasci G, D'Aiuto G, Comella P, Thomas R, Botti G, Di Bonito M, De Rosa V, Iodice G, Rubulotta MR, Comella G; Southern Italy Cooperative Oncology Group (SICOG): Weekly cisplatin, epirubicin and paclitaxel with granulocyte colony-stimulating factor support versus triweekly epirubicin and paclitaxel in locally advanced breast cancer. Final analysis of a SICOG phase III study. Br J Cancer 95: 1005-1012, 2006.
18. Therasse P, Mauriac L, Weinicka-Jaskiewicz M, Bruning P, Cufer T, Bonnefoi H, Tomiak E, Pritchard KI, Hamilton A, Piccart MJ; EORTC: Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide plus filgrastim as neoadjuvant treatment in locally advanced breast cancer: An EORTC-NCIC-SAKK multicenter study. J Clin Oncol 21(5): 843-850, 2003.
19. Smoot RL, Koch CA, Degnim AC, Sterioff S, Donohue JH, Grant CS, Barnes SA, Gullerud RE, Hobday TJ and Farley DR: A single-center experience with inflammatory breast cancer, 1985-2003, Arch Surg 141: 567-573, 2006.
20. von Minckwitz G, Rezai M, Loibl S, Faching PA, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Hanusch C, Kühn T, du Bois A, Blohmer JU, Thomssen C, Da Costa S, Jackisch C, Kaufmann M, Mehta K and Untch M: Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. J Clin Oncol 28(12): 2015-2023, 2010.
21. Cristofanilli M, Valero V, Buzdar AU, Kau SW, Broglio KR, Gonzalez-Angulo AM, Sneige N, Islam R, Ueno NT, Buchholz TA, Singletary SE and Hortobagyi GN: Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease. Cancer 110(7): 1436-1444, 2007.
22. Wedam SB, Low JA, Yang SX, Chow CK, Choyke P, Danforth D, Hewitt SM, Berman A, Steinberg SM, Liewehr DJ, Plehn J, Doshi A, Thomasson D, McCarthy N, Koeppen H, Sherman M, Zujewski J, Camphausen K, Chen H and Swain SM: Anitangiogenic and antitumour effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 24(5): 769-777, 2006.
23. Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, Zambetti M, Vazquez F, Byakhow M, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Baronio R, Feyereislova A, Barton C, Valagussa P and Baselga J: Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with Her2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375(9712): 377-384, 2010.
24. Johnston S, Trudeau M, Kaufman B, Boussen H, Blackwell K, LoRusso P, Lombardi DP, Ben Ahmed S, Citrin DL, DeSilvio ML, Marris J, Westlund RE, Salazar V, Zaks TZ and Spector NL: Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol 26(7): 1066-1072, 2008.
25. Limentani SA, Brufsky AM, Erban JK, Jahanzeb M and Lewis D: Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer. J Clin Oncol 25(10): 1232-1238, 2007.
26. Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gómez H, Dinh P, Fauria K, Van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horváth Z, Coccia-Portugal M, Domont J, Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch M, Gelber RD, Piccart-Gebhart M; NeoALTTO Study Team. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 18;379(9816): 633-640, 2012. Erratum in: Lancet 18;379(9816): 616, 2012.
27. Untch M, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer JU, Hilfrich J, Strumberg D, Fasching PA, Kreienberg R, Tesch H, Hanusch C, Gerber B, Rezai M, Jackisch C, Huober J, Kühn T, Nekljudova V, von Minckwitz G; German Breast Group (GBG); Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Study Group. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol 13(2): 135-144, 2012.
28. von Minckwitz G, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Kreienberg R, Solbach C, Gerber B, Jackisch C, Kunz G, Blohmer JU, Huober J, Hauschild M, Fehm T, Müller BM, Denkert C, Loibl S, Nekljudova V, Untch M; German Breast Group; Arbeitsgemeinschaft Gynäkologische Onkologie-Breast Study Groups. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 26;366(4): 299-309, 2012.
29. Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi G, Szado T, Ratnayake J, Ross G and Valagussa P: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13(1): 25-32, 2012.
30. von Minckwitz G, Eidtmann H, Loibl S, Blohmer JU, Costa SD, Fasching PA, Kreienberg R, Hilfrich J, Gerber B, Hanusch C, Fehm T, Strumberg D, Solbach C, Nekljudova V, Untch M; German Breast Group and Arbeitsgemeinschaft Gynäkologische Onkologie-Brust investigators. Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial. Ann Oncol 22(2): 301-306, 2011.